Pfizer recalls some batches of blood pressure drug over carcinogen presence

1 minute read

A 3D printed Pfizer logo is placed near medicines from the same manufacturer in this illustration taken September 29, 2021. REUTERS/Dado Ruvic/Illustration

Register now for FREE unlimited access to

April 22 (Reuters) - Pfizer (PFE.N) said on Friday it was voluntarily recalling five batches of its Accupril blood pressure tablets after finding elevated levels of a potential cancer-causing agent in the medicine.

The drugmaker said it was not aware of any reports of adverse events related to the recalled batches, which were distributed in the United States and Puerto Rico from December 2019 to April 2022.

Pfizer Canada also recalled all lots of three doses of Accupril on Thursday after finding the same impurity to be above acceptable levels.

Register now for FREE unlimited access to

Pfizer said there was no immediate risk to patients taking this medication, in which the agent, a nitrosamine, was found.

Nitrosamines are common in water and foods but exposure above acceptable levels over long periods of time could increase the risk of cancer.

Pfizer last month also recalled some batches of another blood pressure drug Accuretic and two authorized cheaper versions due to the presence of the possible carcinogen.

Register now for FREE unlimited access to
Reporting by Amruta Khandekar; Editing by Krishna Chandra Eluri

Our Standards: The Thomson Reuters Trust Principles.